Clinical significance of indeterminate quantiFERON-TB Gold plus assay results in hospitalized COVID-19 patients with severe hyperinflammatory syndrome
Autor/a
Solanich, Xavier
Fernández-Huerta, Miguel
Basaez, Celeste
Antolí, Arnau
Rocamora-Blanch, Gemma
Corbella Virós, Xavier
Santin, Miguel
Alcaide, Fernando
Data de publicació
2021ISSN
2077-0383
Resum
Performance of the QuantiFERON-TB Gold Plus (QFT-Plus) assay could be affected by conditions of immune dysregulation. Little is known about the reliability of QTF-Plus in COVID-19 patients. Our aim was to determine the prevalence and the factors related to an indeterminate QFT-Plus test in COVID-19 hospitalized patients, and to analyze its relationship with in-hospital mortality. A retrospective analysis of all hospitalized COVID-19 patients on whom a QTF-Plus assay was performed in a tertiary care public hospital during the first epidemic wave in Spain (March–April 2020). Out of a total of 96 patients included, 34 (35.4%) had an indeterminate result, in all cases due to a lack of response in the mitogen control. Factors related to COVID-19 severity, such as higher lactate dehydrogenase (LDH) (odds ratio [OR] 1.005 [95% confidence interval [CI] 1.002–1.008]) and previous administration of corticosteroids (OR 4.477 [95% CI 1.397–14.345]), were independent predictors for indeterminate QFT-Plus assay. Furthermore, indeterminate results were more frequent among COVID-19 patients who died during hospitalization (29.1% vs. 64.7%; p = 0.005). We conclude that QFT-Plus assay yielded an unexpected, high prevalence of indeterminate results in severe COVID-19 patients. Factors related to worse COVID-19 outcome, such as LDH, as well as corticosteroid use before the QFT-Plus assay, seem to be predictors for an indeterminate result. The role of an indeterminate QFT-Plus result in predicting COVID-19 severity and mortality should be evaluated.
Tipus de document
Article
Versió del document
Versió publicada
Llengua
Anglès
Matèries (CDU)
61 - Medicina
616.9 - Malalties infeccioses i contagioses. Febres
Paraules clau
COVID-19 (Malaltia)
Corticosteroides
Resposta immunitària
COVID-19
Corticosteroides
Respuesta inmune
COVID-19
Corticosteroids
Immune response
Pàgines
8
Publicat per
MDPI
Col·lecció
10;
Publicat a
Journal of Clinical Medicine
Citació
Solanich, Xavier; Fernández-Huerta, Miguel; Basaez, Celeste [et al.]. Clinical significance of indeterminate quantiFERON-TB Gold plus assay results in hospitalized COVID-19 patients with severe hyperinflammatory syndrome. Journal of Clinical Medicine, 2021, 10, 918. Disponible en: <https://www.mdpi.com/2077-0383/10/5/918>. Fecha de acceso: 31 may. 2021. DOI: 10.3390/jcm10050918
Aquest element apareix en la col·lecció o col·leccions següent(s)
- Ciències de la Salut [725]
Drets
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Excepte que s'indiqui una altra cosa, la llicència de l'ítem es descriu com https://creativecommons.org/licenses/by/4.0/